148 related articles for article (PubMed ID: 22634372)
21. Prevalence and clinical features of LRRK2 mutations in patients with Parkinson's disease in southern Spain.
Gao L; Gómez-Garre P; Díaz-Corrales FJ; Carrillo F; Carballo M; Palomino A; Díaz-Martín J; Mejías R; Vime PJ; López-Barneo J; Mir P
Eur J Neurol; 2009 Aug; 16(8):957-60. PubMed ID: 19473361
[TBL] [Abstract][Full Text] [Related]
22. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
23. Leucine-rich repeat kinase 2 and alternative splicing in Parkinson's disease.
Elliott DA; Kim WS; Gorissen S; Halliday GM; Kwok JB
Mov Disord; 2012 Jul; 27(8):1004-11. PubMed ID: 22528366
[TBL] [Abstract][Full Text] [Related]
24. Mouse models for LRRK2 Parkinson's disease.
Xu Q; Shenoy S; Li C
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S186-9. PubMed ID: 22166430
[TBL] [Abstract][Full Text] [Related]
25. Gene and MicroRNA transcriptome analysis of Parkinson's related LRRK2 mouse models.
Dorval V; Mandemakers W; Jolivette F; Coudert L; Mazroui R; De Strooper B; Hébert SS
PLoS One; 2014; 9(1):e85510. PubMed ID: 24427314
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2.
Ruiz-Martínez J; de la Riva P; Rodríguez-Oroz MC; Mondragón Rezola E; Bergareche A; Gorostidi A; Gago B; Estanga A; Larrañaga N; Sarasqueta C; López de Munain A; Martí Massó JF
Mov Disord; 2014 May; 29(6):750-5. PubMed ID: 24357540
[TBL] [Abstract][Full Text] [Related]
27. [Advance of the study on LRRK2 gene in Parkinson's disease].
Zhang Y; Chen S
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):657-9. PubMed ID: 19065525
[TBL] [Abstract][Full Text] [Related]
28. The parkinson's disease-associated LRRK2 mutation R1441G inhibits neuronal differentiation of neural stem cells.
Bahnassawy L; Nicklas S; Palm T; Menzl I; Birzele F; Gillardon F; Schwamborn JC
Stem Cells Dev; 2013 Sep; 22(18):2487-96. PubMed ID: 23600457
[TBL] [Abstract][Full Text] [Related]
29. Low frequency of common LRRK2 mutations in Mexican patients with Parkinson's disease.
Yescas P; López M; Monroy N; Boll MC; Rodríguez-Violante M; Rodríguez U; Ochoa A; Alonso ME
Neurosci Lett; 2010 Nov; 485(2):79-82. PubMed ID: 20727385
[TBL] [Abstract][Full Text] [Related]
30. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
Kethiri RR; Bakthavatchalam R
Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
[TBL] [Abstract][Full Text] [Related]
31. Identification of three novel LRRK2 mutations associated with Parkinson's disease in a Calabrian population.
Anfossi M; Colao R; Gallo M; Bernardi L; Conidi ME; Frangipane F; Vasso F; Puccio G; Clodomiro A; Mirabelli M; Curcio SA; Torchia G; Smirne N; Di Lorenzo R; Maletta R; Bruni AC
J Alzheimers Dis; 2014; 38(2):351-7. PubMed ID: 23963289
[TBL] [Abstract][Full Text] [Related]
32. Effects of sevoflurane on leucine-rich repeat kinase 2-associated Drosophila model of Parkinson's disease.
Shan Z; Cai S; Zhang T; Kuang L; Wang Q; Xiu H; Wen J; Gu H; Xu K
Mol Med Rep; 2015 Mar; 11(3):2062-70. PubMed ID: 25406035
[TBL] [Abstract][Full Text] [Related]
33. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study.
Hulihan MM; Ishihara-Paul L; Kachergus J; Warren L; Amouri R; Elango R; Prinjha RK; Upmanyu R; Kefi M; Zouari M; Sassi SB; Yahmed SB; El Euch-Fayeche G; Matthews PM; Middleton LT; Gibson RA; Hentati F; Farrer MJ
Lancet Neurol; 2008 Jul; 7(7):591-4. PubMed ID: 18539535
[TBL] [Abstract][Full Text] [Related]
34. Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients.
Floris G; Cannas A; Solla P; Murru MR; Tranquilli S; Corongiu D; Rolesu M; Cuccu S; Sardu C; Marrosu F; Marrosu MG
Parkinsonism Relat Disord; 2009 May; 15(4):277-80. PubMed ID: 18805725
[TBL] [Abstract][Full Text] [Related]
35. An emerging role for LRRK2 in the immune system.
Dzamko N; Halliday GM
Biochem Soc Trans; 2012 Oct; 40(5):1134-9. PubMed ID: 22988878
[TBL] [Abstract][Full Text] [Related]
36. Autonomic dysfunction in parkinsonian LRRK2 mutation carriers.
Tijero B; Gómez Esteban JC; Somme J; Llorens V; Lezcano E; Martinez A; Rodríguez T; Berganzo K; Zarranz JJ
Parkinsonism Relat Disord; 2013 Oct; 19(10):906-9. PubMed ID: 23764467
[TBL] [Abstract][Full Text] [Related]
37. Genetics of Parkinson's disease: LRRK2 on the rise.
Brice A
Brain; 2005 Dec; 128(Pt 12):2760-2. PubMed ID: 16311269
[No Abstract] [Full Text] [Related]
38. Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson's disease patients.
Dzamko N; Chua G; Ranola M; Rowe DB; Halliday GM
J Parkinsons Dis; 2013; 3(2):145-52. PubMed ID: 23938344
[TBL] [Abstract][Full Text] [Related]
39. Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson's disease.
Bardien S; Lesage S; Brice A; Carr J
Parkinsonism Relat Disord; 2011 Aug; 17(7):501-8. PubMed ID: 21641266
[TBL] [Abstract][Full Text] [Related]
40. LRRK2 delays degradative receptor trafficking by impeding late endosomal budding through decreasing Rab7 activity.
Gómez-Suaga P; Rivero-Ríos P; Fdez E; Blanca Ramírez M; Ferrer I; Aiastui A; López De Munain A; Hilfiker S
Hum Mol Genet; 2014 Dec; 23(25):6779-96. PubMed ID: 25080504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
